Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
| Main Authors: | , , , , , , |
|---|---|
| Format: | Conference item |
| Language: | English |
| Published: |
Oxford University Press
2021
|